AstraZeneca PLC (AZN.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
As of 11:34AM BST. Market open.
Loading interactive chart…
- Yahoo Finance UK
How to minimise a capital gains tax impact on your investments
Multi-asset funds have been put forward as one way to manage the impact of a mooted capital gains tax hike on investment portfolios.
- Zacks
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
- Business Wire
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
WILMINGTON, Del., October 03, 2024--AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
© 2024 Yahoo. All rights reserved.